Glendale, CA (PRWEB) September 03, 2013 Audio-Digest Foundation Announces the Release of Gastroenterology Volume 27, Issue 11: Celiac Disease. The goal of this program is to improve the diagnosis and management of patients with celiac disease (CD). After hearing and assimilating this program, the clinician will be better able to: 1. Review the pathophysiology of CD 2. Assess the clinical manifestations of CD 3. Analyze the histologic findings associated with CD 4. Implement genetic and serologic testing for CD 5. Formulate a multidisciplinary management plan for patients diagnosed with CD The original programs were presented by Dora M. Lam-Himlin, MD, Assistant Professor of Pathology and Senior Associate Consultant, Mayo Clinic, Arizona, Phoenix, and Joseph A. Murray, MD, Professor of Medicine, Consultant, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN. Audio-Digest Foundation, the largest independent publisher of Continuing Medical Education in the world, records over 10,000 hours of lectures every year in anesthesiology, emergency medicine, family practice, gastroenterology, general surgery, internal medicine, neurology, obstetrics/gynecology, oncology, ophthalmology, orthopaedics, otolaryngology, pediatrics, psychology, and urology, by the leading medical researchers at the top laboratories, universities, and institutions. Recent researchers have hailed from Harvard, Cedars-Sinai, Mayo Clinic, UCSF, The University of Chicago Pritzker School … Continue reading →

Public release date: 3-Sep-2013 [ | E-mail | Share ] Contact: Jennifer Schutz newsbureau@mayo.edu 507-284-5005 Mayo Clinic ROCHESTER, Minn. -- Mayo Clinic researchers have found a way to resynchronize cardiac motion following a heart attack using stem cells. Scientists implanted engineered stem cells, also known as induced pluripotent stem (iPS) cells, into damaged regions of mouse hearts following a heart attack. This regenerative approach successfully targeted the origin of abnormal cardiac motion, preventing heart failure. The findings appear in the September issue of the Journal of Physiology. MULTIMEDIA ALERT: Video resources, including interviews with Drs. Terzic and Yamada, are available for journalists at the Mayo Clinic News Network. "The discovery introduces -- for the first time -- stem cell-based 'biological resynchronization' as a novel means to treat cardiac dyssynchrony," says Andre Terzic, M.D., Ph.D., senior author of the study. Dr. Terzic is the Michael S. and Mary Sue Shannon Family Director, Center for Regenerative Medicine, and the Marriott Family Professor of Cardiovascular Diseases Research. Muscle damage following a heart attack may disrupt normal heart conduction, resulting in a condition known as cardiac dyssynchrony. Current therapy uses pacing devices such as pacemakers; however, many patients with advanced heart failure do not … Continue reading →

RANCHO CORDOVA, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- ThermoGenesis Corp. (KOOL) ("ThermoGenesis"), a leading supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, today announced that Matthew Plavan, Chief Executive Officer of ThermoGenesis, and Kenneth Harris, Chairman and Chief Executive Officer of TotipotentRx Corporation, will present at the Rodman & Renshaw(R) Annual Global Investment Conference, being held at the Millennium Broadway Hotel in New York City. The presentation will take place on Monday, September 9, 2013 at 12:05 PM Eastern Time. The presentation will be webcast and available to the public online at wsw.com/webcast/rrshq23/kool. A replay will be available for 30 days after the presentation. About ThermoGenesis Corp. ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood and bone marrow processing systems and companion disposable products that enable the separation, processing and preservation of cell and tissue therapy products. These include: TotipotentRx and ThermoGenesis Corp recently announced their entry into a merger agreement which will operate under the name Cesca Therapeutics. The merger is subject to TotipotentRx and ThermoGenesis stockholder approval. Additional Information In connection with the merger, ThermoGenesis intends to file a registration statement (including a prospectus) on … Continue reading →

Sep. 3, 2013 Mayo Clinic researchers have found a way to resynchronize cardiac motion following a heart attack using stem cells. Scientists implanted engineered stem cells, also known as induced pluripotent stem (iPS) cells, into damaged regions of mouse hearts following a heart attack. This regenerative approach successfully targeted the origin of abnormal cardiac motion, preventing heart failure. The findings appear in the September issue of the Journal of Physiology. "The discovery introduces -- for the first time -- stem cell-based 'biological resynchronization' as a novel means to treat cardiac dyssynchrony," says Andre Terzic, M.D., Ph.D., senior author of the study. Dr. Terzic is the Michael S. and Mary Sue Shannon Family Director, Center for Regenerative Medicine, and the Marriott Family Professor of Cardiovascular Diseases Research. Muscle damage following a heart attack may disrupt normal heart conduction, resulting in a condition known as cardiac dyssynchrony. Current therapy uses pacing devices such as pacemakers; however, many patients with advanced heart failure do not respond favorably to these devices because heart tissue must be healthy for optimal outcome. Stem cell-based repair would offer a new solution to patients who would otherwise be resistant to device-based resynchronization. "A high-resolution ultrasound revealed harmonized pumping … Continue reading →

Public release date: 3-Sep-2013 [ | E-mail | Share ] Contact: Shaun Mason smason@mednet.ucla.edu 310-206-2805 University of California - Los Angeles Four researchers from UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have received Early Translational Research Awards totaling approximately $13 million from the California Institute for Regenerative Medicine, the state's stem cell agency. The UCLA researchers received four of the 12 total awards; no other institution received more than one. The Independent Citizens Oversight Committee, CIRM's governing body, announced at its Aug. 28 meeting in La Jolla, Calif., that grant recipients included Dr. Jerome Zack, professor of medicine and microbiology, immunology and molecular genetics; Dr. Robert Reiter, Bing Professor of Urologic Research; Dr. Donald Kohn, professor of pediatrics and microbiology, immunology and molecular genetics in the life sciences; and Dr. Gerald Lipshutz, associate professor-in-residence of surgery, urology and medicine. The grants are part of CIRM's Early Translational Research Initiative, which aims to advance promising, innovative discoveries using stem cells. In this "early translation" phase, scientists are expected to do research that will result in the development of drugs or cellular therapies to be used in FDA-approved clinical trials, translating discoveries from the laboratory to … Continue reading →

04.09.2013 - (idw) VDI/VDE Innovation + Technik GmbH On the 1-2 October leading industrial and academic experts, national authorities, and European Commission representatives will meet for the 2013 European Technology Platform on Nanomedicine (ETPN) Annual Event and General Assembly. Within the two days leading experts and specialists from all over Europe will discuss the implementation of recommendations identified by the nanomedicine community that will shape the future of the sector in Europe. The event takes place in Grenoble, France and is organised by CEA-Leti, a leading French research and technology organisation focused on nanotechnologies and their applications in healthcare. The event aims to provide further details on the ETPNs recommendations for nanomedicine under the upcoming Research Framework Programme Horizon 2020, the EU's main instrument for research funding in Europe, launching from 2014-2020. Patrick Boisseau, chairman of the ETPN, said: The first line has been crossed with the official renewal of the ETPN as a European Technology Platform, which represents an increasingly key element in the European innovation ecosystem and a main bridge between the community and the European Commission that is needed to implement Horizon 2020. He added, We look forward to welcoming all European stakeholders involved in the nanomedicine … Continue reading →

The global nanomedicine market has been forecast to increase at a compound annual growth rate (CAGR) of 12.57% through to 2016, driven by the emergence of nanorobotics, and the increasing use of novel nanomaterials. Nanomedicine is already an established market. Unlike some other potential applications of nanotechnology, which are still largely experimental, nanomedicine has already produced a number of significant products in which the nano dimension has made a significant contribution to product effectiveness. Nanomedicine is a large industry, with nanomedicine sales reaching $72.8 billion in 2011, and with over 200 companies and 38 products worldwide, a minimum of $3.8 billion in nanotechnology R&D is being invested every year. As the nanomedicine industry continues to grow, it is expected to have a significant impact on the economy. Nanomedicine is the medical application of nanotechnology. Nanomedicine ranges from the medical applications of nanomaterials, to nanoelectronic biosensors, and even possible future applications of molecular nanotechnology. Current problems for nanomedicine involve understanding the issues related to toxicity and environmental impact of nanoscale materials. One nanometer is one-millionth of a millimetre. Over the years, research activities in the healthcare industry have changed significantly. There has been a paradigm shift from blockbuster drugs to a … Continue reading →